Comparison of the Efficacy of Immune Checkpoint Inhibitors Combined with Chemotherapy Versus Bevacizumab Combined with Chemotherapy in Advanced Driver Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study
Wanwan Chen,1 Qiang Dai,2 Zhe Ye,3 Yiwei Huang3 1Department of Pathology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 2Department of Oncology, the Third Affiliated Hospital of Wenzhou Medical Univ...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | Journal of Multidisciplinary Healthcare |
| Subjects: | |
| Online Access: | https://www.dovepress.com/comparison-of-the-efficacy-of-immune-checkpoint-inhibitors-combined-wi-peer-reviewed-fulltext-article-JMDH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Wanwan Chen,1 Qiang Dai,2 Zhe Ye,3 Yiwei Huang3 1Department of Pathology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 2Department of Oncology, the Third Affiliated Hospital of Wenzhou Medical University (Ruian People’s Hospital), Wenzhou, Zhejiang, 325200, People’s Republic of China; 3Department of Radiotherapy, the Third Affiliated Hospital of Wenzhou Medical University (Ruian People’s Hospital), Wenzhou, Zhejiang, 325200, People’s Republic of ChinaCorrespondence: Yiwei Huang, Email ghp503@126.comObjective: To compare the efficacy and safety of immune checkpoint inhibitors (ICIs) plus chemotherapy versus bevacizumab plus chemotherapy in advanced driver gene-negative non-squamous non-small cell lung cancer (NS-NSCLC).Methods: This retrospective cohort study included 199 patients treated from October 2015 to January 2022. Group A (n=103) received ICIs plus chemotherapy (pemetrexed + cisplatin), while Group B (n=96) received bevacizumab plus the same chemotherapy. Outcomes included treatment response, serum tumor markers (CEA, CA-125, CA-199), immunoglobulins (IgA, IgG, IgM), adverse reactions, and survival [progression-free survival (PFS), overall survival (OS)].Results: Group A had a significantly higher objective response rate (59.22% vs 36.46%, P=0.001). Tumor marker levels decreased more in Group A (P< 0.05), while declines in immunoglobulin levels were less pronounced (P< 0.05). Adverse events were similar between groups (P> 0.05). Group A had a longer median PFS (11.13 vs 7.37 months, P< 0.05), and a non-significant trend toward longer OS (20.87 vs 18.4 months, P=0.159).Conclusion: ICIs combined with chemotherapy improved treatment efficacy and PFS compared to bevacizumab-based therapy in advanced driver gene-negative NS-NSCLC, with manageable safety and less impact on immune function.Keywords: immune checkpoint inhibitors, chemotherapy, bevacizumab, non-squamous non-small cell lung cancer, driver gene-negative |
|---|---|
| ISSN: | 1178-2390 |